Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.

Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, Jankovic M, Corti D, Lanzavecchia A, Nussenzweig MC.

J Exp Med. 2010 Aug 30;207(9):1995-2002. doi: 10.1084/jem.20101176. Epub 2010 Aug 2.

PMID:
20679402
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Bhattacharyya S, Rajan RE, Swarupa Y, Rathore U, Verma A, Udaykumar R, Varadarajan R.

J Biol Chem. 2010 Aug 27;285(35):27100-10. doi: 10.1074/jbc.M110.152272. Epub 2010 Jun 17.

PMID:
20558728
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES, Perez LG, Haynes BF, Liao HX, Labranche CC, Korber BT, Montefiori DC.

J Virol. 2011 Sep;85(18):9286-99. doi: 10.1128/JVI.02286-10. Epub 2011 Jul 6.

PMID:
21734041
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.

Evans MC, Phung P, Paquet AC, Parikh A, Petropoulos CJ, Wrin T, Haddad M.

BMC Bioinformatics. 2014 Mar 19;15:77. doi: 10.1186/1471-2105-15-77.

PMID:
24646213
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.

Joyce MG, Kanekiyo M, Xu L, Biertümpfel C, Boyington JC, Moquin S, Shi W, Wu X, Yang Y, Yang ZY, Zhang B, Zheng A, Zhou T, Zhu J, Mascola JR, Kwong PD, Nabel GJ.

J Virol. 2013 Feb;87(4):2294-306. doi: 10.1128/JVI.02717-12. Epub 2012 Dec 12.

PMID:
23236069
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW.

J Virol. 1993 Oct;67(10):6179-91.

PMID:
7690420
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.

PMID:
16551265
[PubMed - indexed for MEDLINE]
8.

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.

Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ.

J Virol. 2009 May;83(10):5077-86. doi: 10.1128/JVI.02600-08. Epub 2009 Mar 4.

PMID:
19264769
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.

Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L; NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF.

Nature. 2013 Apr 25;496(7446):469-76. doi: 10.1038/nature12053. Epub 2013 Apr 3.

PMID:
23552890
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

[Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].

Granados-González V, Piedrahita LD, Martínez M, Genin C, Riffard S, Urcuqui-Inchima S.

Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1. Review. Spanish.

PMID:
19409660
[PubMed - indexed for MEDLINE]
11.

Challenges for structure-based HIV vaccine design.

Schief WR, Ban YE, Stamatatos L.

Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Review.

PMID:
20048708
[PubMed - indexed for MEDLINE]
12.

High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.

Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Sci Transl Med. 2012 Jul 11;4(142):142ra96. doi: 10.1126/scitranslmed.3003752.

PMID:
22786681
[PubMed - indexed for MEDLINE]
Free Article
13.

Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.

Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.

J Pept Sci. 1995 Mar-Apr;1(2):109-23.

PMID:
9222988
[PubMed - indexed for MEDLINE]
14.

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Kwong PD, Mascola JR.

Immunity. 2012 Sep 21;37(3):412-25. doi: 10.1016/j.immuni.2012.08.012. Review.

PMID:
22999947
[PubMed - indexed for MEDLINE]
Free Article
15.

Mapping of two new human B-cell epitopes on HIV-1 gp120.

Kusk P, Holmbäck K, Lindhardt BO, Hulgaard EF, Bugge TH.

AIDS. 1992 Dec;6(12):1451-6.

PMID:
1283518
[PubMed - indexed for MEDLINE]
16.

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.

Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF.

J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27.

PMID:
21795340
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR.

Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.

PMID:
20616233
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M; NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR.

Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532. Epub 2011 Aug 11.

PMID:
21835983
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The antigenic structure of the HIV gp120 envelope glycoprotein.

Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG.

Nature. 1998 Jun 18;393(6686):705-11.

PMID:
9641684
[PubMed - indexed for MEDLINE]
20.

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.

PLoS One. 2011 Jan 26;6(1):e16074. doi: 10.1371/journal.pone.0016074.

PMID:
21297864
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk